| World Health Organization package of interventions for rehabilitation for cancer: a MASCC-endorsed resource for global action to address unmet rehabilitation needs of people … NH Hart, NL Stout, D Haywood, FD Ashbury, RJ Chan, MI Fitch, M Jefford, ... Supportive Care in Cancer 32 (7), 417, 2024 | | 2024 |
| The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer KCC Johnson, A Ni, D Quiroga, AC Pariser, PK Sudheendra, NO Williams, ... npj Breast Cancer 10 (1), 49, 2024 | | 2024 |
| Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer JS Sukumar, S Sardesai, A Ni, N Williams, K Johnson, D Quiroga, ... Cancer Medicine 13 (12), 2024 | | 2024 |
| Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC). M Taylor, S Reddy, P Ashok Kumar, D Hariri, E Sokol, S Sivakumar, ... Journal of Clinical Oncology 42 (16_suppl), 1092-1092, 2024 | | 2024 |
| Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. P Tarantino, D Lee, J Foldi, PR Soulos, CP Gross, T Grinda, EP Winer, ... Journal of Clinical Oncology 42 (16_suppl), 1077-1077, 2024 | | 2024 |
| Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier … LV Ravani, P Calomeni, M Vilbert, T Madeira, M Wang, D Deng, L Testa, ... Journal of Clinical Oncology 42 (16_suppl), 1065-1065, 2024 | | 2024 |
| Aromatase inhibitor musculoskeletal toxicity (AIMT) in patients (pts) with early breast cancer (EBC): Prevalence, management, and association with non-adherence to AI. P Lapidari, MB Lustberg, J Havas, M Pagliuca, MAB Franzoi, G Menvielle, ... Journal of Clinical Oncology 42 (16_suppl), 12122-12122, 2024 | | 2024 |
| Episodic future thinking: A behavioral intervention to promote weight loss in breast cancer survivors. JS Sukumar, MB Lustberg, J Stein, P Schnell, J King, D Schimming, ... Journal of Clinical Oncology 42 (16_suppl), e22541-e22541, 2024 | | 2024 |
| Personalized risk assessment of new onset depression in long-term cancer survivors. M Taylor, SJ Westvold, JB Long, T Hyslop, SY Wang, M Cecchini, ... Journal of Clinical Oncology 42 (16_suppl), e13798-e13798, 2024 | | 2024 |
| Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer. NA Fischbach, B Zhou, Y Deng, K Parsons, A Shelton, MB Lustberg Journal of Clinical Oncology 42 (16_suppl), e24140-e24140, 2024 | | 2024 |
| Predicting peripheral neuropathy following neoadjuvant therapy in patients with breast cancer. B Feiger, M Biancalana, A Shelton, K Blenman, MB Lustberg Journal of Clinical Oncology 42 (16_suppl), e12639-e12639, 2024 | | 2024 |
| Neurofilament light chains: A biomarker for vincristine-related neuropathy. GA McNally, M Xu, T Voorhees, RA Baiocchi, DA Bond, N Epperla, ... Journal of Clinical Oncology 42 (16_suppl), 12114-12114, 2024 | | 2024 |
| Characterization of time toxicity in older patients with metastatic breast cancer SY Atre, PR Soulos, NM Kuderer, CP Gross, LVM Baum, MA Dinan, ... Breast Cancer Research and Treatment, 1-10, 2024 | | 2024 |
| Promise and perils of large language models for cancer survivorship and supportive care DS Bitterman, A Downing, J Maués, M Lustberg Journal of Clinical Oncology 42 (14), 1607-1611, 2024 | 1 | 2024 |
| Abstract PO2-13-09: Delayed alopecia among breast cancer survivors S Premji, K Ruddy, N Larson, C Loprinzi, B Dulmage, M Lustberg, ... Cancer Research 84 (9_Supplement), PO2-13-09-PO2-13-09, 2024 | | 2024 |
| Abstract PO4-15-08: Comprehensive genomic profiling of HER2-low advanced breast cancers A Kahn, E Sokol, J Ross, M Pelletier, N Fischbach, L Pusztai, M Lustberg Cancer Research 84 (9_Supplement), PO4-15-08-PO4-15-08, 2024 | | 2024 |
| Abstract PO4-17-02: A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable … J O'Shaughnessy, R Basho, M Lustberg, GH Lyman, M Prahladan, ... Cancer Research 84 (9_Supplement), PO4-17-02-PO4-17-02, 2024 | | 2024 |
| Abstract PO3-10-01: How The Financial Toxicity of Metastatic Breast Cancer Affects Single Mothers with Young Children: Where Disparities Lie and Outcomes For Quality of Life R Lombardi, M lustberg Cancer Research 84 (9_Supplement), PO3-10-01-PO3-10-01, 2024 | | 2024 |
| Abstract PO5-19-04: EVOLVE: An Ambispective, Patient-Centered, Real-World Early-Stage Breast Cancer Study in the United States H Friedler, M Tierney, M Baker, G Hanson, J Briceno, K Smith, M Baber, ... Cancer Research 84 (9_Supplement), PO5-19-04-PO5-19-04, 2024 | | 2024 |
| Abstract PO2-06-02: Characteristics and Treatment Patterns of de novo Oligometastatic Stage IV Breast Cancer: A Single-Center Retrospective Cohort Study D Blansky, M Lustberg, L Pusztai, M Rozenblit Cancer Research 84 (9_Supplement), PO2-06-02-PO2-06-02, 2024 | | 2024 |
Sagar SardesaiThe Ohio State University在 osumc.edu 的电子邮件经过验证
